INSMED INC's ticker is INSM and the CUSIP is 457669307. A total of 254 filers reported holding INSMED INC in Q3 2023. The put-call ratio across all filers is 6.19 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,128,937 | +49.0% | 361,542 | +24.5% | 0.00% | 0.0% |
| Q2 2023 | $6,125,435 | +9.9% | 290,305 | -11.2% | 0.00% | 0.0% |
| Q1 2023 | $5,575,452 | +650.8% | 327,006 | +779.9% | 0.00% | – |
| Q4 2022 | $742,577 | -89.0% | 37,166 | -88.1% | 0.00% | -100.0% |
| Q3 2022 | $6,731,000 | +184.0% | 312,485 | +159.9% | 0.00% | – |
| Q2 2022 | $2,370,000 | -34.2% | 120,229 | -21.6% | 0.00% | – |
| Q1 2022 | $3,604,000 | -30.0% | 153,383 | -18.9% | 0.00% | – |
| Q4 2021 | $5,150,000 | +111.8% | 189,110 | +114.2% | 0.00% | – |
| Q3 2021 | $2,431,000 | +86.1% | 88,272 | +92.4% | 0.00% | – |
| Q2 2021 | $1,306,000 | -64.7% | 45,875 | -57.7% | 0.00% | – |
| Q1 2021 | $3,696,000 | -2.4% | 108,522 | -4.6% | 0.00% | – |
| Q4 2020 | $3,788,000 | -11.8% | 113,778 | -14.8% | 0.00% | – |
| Q3 2020 | $4,294,000 | -9.7% | 133,612 | -22.6% | 0.00% | -100.0% |
| Q2 2020 | $4,755,000 | +26.0% | 172,643 | -26.7% | 0.00% | 0.0% |
| Q1 2020 | $3,774,000 | -78.7% | 235,446 | -68.3% | 0.00% | -83.3% |
| Q4 2019 | $17,741,000 | +69.2% | 742,919 | +25.0% | 0.01% | +50.0% |
| Q3 2019 | $10,487,000 | -75.4% | 594,443 | -64.3% | 0.00% | -20.0% |
| Q2 2019 | $42,612,000 | +143.2% | 1,664,594 | +176.1% | 0.01% | -37.5% |
| Q1 2019 | $17,524,000 | +168.4% | 602,800 | +21.1% | 0.01% | +300.0% |
| Q4 2018 | $6,528,000 | -55.6% | 497,600 | -31.6% | 0.00% | -60.0% |
| Q3 2018 | $14,700,000 | +83.5% | 727,000 | +114.6% | 0.01% | +66.7% |
| Q2 2018 | $8,010,000 | -37.8% | 338,700 | -40.7% | 0.00% | -40.0% |
| Q1 2018 | $12,872,000 | +77.2% | 571,600 | +145.3% | 0.01% | +150.0% |
| Q4 2017 | $7,265,000 | -68.8% | 233,000 | -68.8% | 0.00% | -77.8% |
| Q3 2017 | $23,321,000 | +471.5% | 747,200 | +214.2% | 0.01% | +350.0% |
| Q2 2017 | $4,081,000 | -31.7% | 237,800 | -30.3% | 0.00% | -33.3% |
| Q1 2017 | $5,978,000 | +35.9% | 341,400 | +2.7% | 0.00% | +50.0% |
| Q4 2016 | $4,399,000 | +35.3% | 332,572 | +48.5% | 0.00% | 0.0% |
| Q3 2016 | $3,251,000 | +24.4% | 223,900 | -15.5% | 0.00% | +100.0% |
| Q2 2016 | $2,613,000 | -24.4% | 265,005 | -2.9% | 0.00% | 0.0% |
| Q1 2016 | $3,457,000 | -12.9% | 272,847 | +24.8% | 0.00% | 0.0% |
| Q4 2015 | $3,968,000 | -11.2% | 218,616 | -9.1% | 0.00% | 0.0% |
| Q3 2015 | $4,467,000 | +5.9% | 240,523 | +39.2% | 0.00% | -50.0% |
| Q2 2015 | $4,219,000 | +26.5% | 172,767 | +7.8% | 0.00% | 0.0% |
| Q1 2015 | $3,334,000 | +5.1% | 160,300 | -21.8% | 0.00% | +100.0% |
| Q4 2014 | $3,172,000 | +7.4% | 205,063 | -9.4% | 0.00% | 0.0% |
| Q3 2014 | $2,953,000 | -81.8% | 226,322 | -72.1% | 0.00% | -83.3% |
| Q2 2014 | $16,208,000 | -19.2% | 811,193 | -23.0% | 0.01% | -33.3% |
| Q1 2014 | $20,068,000 | +224.8% | 1,053,940 | +190.1% | 0.01% | +200.0% |
| Q4 2013 | $6,179,000 | +165.1% | 363,268 | +143.3% | 0.00% | +200.0% |
| Q3 2013 | $2,331,000 | -41.1% | 149,314 | -54.9% | 0.00% | -66.7% |
| Q2 2013 | $3,959,000 | – | 331,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Asymmetry Capital Management, L.P. | 250,584 | $4,420,000 | 9.48% |
| Palo Alto Investors LP | 7,239,649 | $127,707,000 | 8.51% |
| Foresite Capital Management IV, LLC | 1,429,518 | $25,217,000 | 8.15% |
| First Light Asset Management, LLC | 1,294,743 | $22,839,000 | 3.45% |
| Foresite Capital Management II, LLC | 915,016 | $16,141,000 | 3.41% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 356,600 | $6,287,000 | 2.90% |
| ACUTA CAPITAL PARTNERS, LLC | 220,000 | $3,881,000 | 2.80% |
| EMERALD ADVISERS, LLC | 984,987 | $17,375,000 | 0.81% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 911,936 | $16,087,000 | 0.71% |
| Rock Springs Capital Management LP | 890,000 | $15,700,000 | 0.63% |